论文部分内容阅读
用于肿瘤治疗的177Lu标记放射性药物的研究成为核医学研究的重要方向。本工作对177Lu标记生长抑素类似物DOTA-TOC的标记方法进行了研究,优化了标记条件,并评价了177Lu-DOTA-TOC在正常昆明小鼠与人胰腺癌PANC-1模型动物中的体内分布特点。在最佳标记条件下(DOTA-TOC25μg,标记介质pH=4.5,于90℃下反应30min),经SEP-PAK
The research on 177Lu labeled radiopharmaceuticals for cancer treatment has become an important direction in nuclear medicine research. In this work, the labeling method of 177Lu labeled somatostatin analogue DOTA-TOC was studied and the labeling conditions were optimized. The 177Lu-DOTA-TOC was evaluated in vivo in normal Kunming mice and human pancreatic cancer PANC-1 model animals Distribution characteristics. Under optimal labeling conditions (DOTA-TOC 25μg, labeling medium pH = 4.5, reaction at 90 ℃ for 30min)